It’s time to meet a biosimilar partner that’s as committed to your patients as you are.
At Accord BioPharma, we believe in the power of biosimilars to reshape the future of treatment. We’re advancing immunology with the support of Intas, an established global leader with nearly five decades of experience.
Intas has registered more than 10,000 medications in over 85 countries, including the EU and US. We are committed to delivering patients the medications they need. For example, Accord Healthcare provides nearly 1 out of every 9 medicines used in the UK.
We offer one of the largest biosimilar pipelines globally, featuring:
Everyone deserves access to the latest life-changing treatments—and that’s our focus. With a robust pipeline of 7 biosimilars in immunology globally, we are dedicated to shaping the future of care for millions of people with immune-modulated conditions.
We’re driving significant advancements in immunology and transforming conventional treatment options by improving affordability and availability. Our recent success with two biosimilar FDA approvals demonstrates our unwavering dedication to making biosimilars mainstream in everything we do.
Our commitment goes beyond medicine–it’s about simplifying your work and supporting patient care.
We streamline the experience for you and your patients through partnerships with wholesalers, GPOs, IDNs, mail order, retail, and specialty pharmacies, ensuring a seamless transition and enhanced care.
AccordCares®, our patient support program, can ease the burden of copay benefits investigation, prior authorization, accessing billing and coding information, and identifying alternate coverage relevant to your practice. This program, like everything we do, is dedicated to you and your patients.
That commitment is also reflected in AccordConnects®, our inventory management system, which is seamlessly accessible with AccordCares®, helping practices to match their inventory needs with the patients they treat with Accord products.
Together, we can drive the next leap in immunology
by focusing on what truly matters to patients.
To schedule an appointment with a payer or clinical executive, please fill in the information below.
Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.
CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression, have been observed, which may contribute to paralysis with or without fatal complications.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.
Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.
Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.
Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.
Monitor serum levels of testosterone following injection of CAMCEVI.
Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.
The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.
Click here for full Prescribing Information.
©2026 Accord BioPharma, Inc. All rights reserved WSB-ABI-2400001
